Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Pembrolizumab in Treating Patients With Desmoplastic Melanoma That Can or Cannot Be Removed by Surgery

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02775851
Recruitment Status : Recruiting
First Posted : May 18, 2016
Last Update Posted : October 4, 2019
Sponsor:
Information provided by (Responsible Party):
National Cancer Institute (NCI)

Brief Summary:
This pilot phase II trial studies how well pembrolizumab works in treating patients with desmoplastic melanoma (DM) that can or cannot be removed by surgery (unresectable). Monoclonal antibodies, like pembrolizumab, may block specific proteins which may strengthen the immune system and control tumor growth.

Condition or disease Intervention/treatment Phase
Desmoplastic Melanoma Biological: Pembrolizumab Procedure: Therapeutic Conventional Surgery Phase 2

Detailed Description:

PRIMARY OBJECTIVES:

I. To evaluate the pathologic complete response rate (pCR) in patients with resectable desmoplastic melanoma treated with neoadjuvant MK-3475 (pembrolizumab). (Cohort A) II. To evaluate the complete response rate (confirmed and unconfirmed) in patients with unresectable desmoplastic melanoma treated with MK-3475 (pembrolizumab). (Cohort B)

SECONDARY OBJECTIVES:

I. To estimate the 9 week response rate (RR) (unconfirmed complete and partial responses) among patients with measurable disease. (Cohort A) II. To estimate the median overall survival (OS). (Cohort A) III. To evaluate safety and tolerability of MK-3475 (pembrolizumab) in the neoadjuvant setting. (Cohort A) IV. To estimate the median progression-free survival (PFS). (Cohort B) V. To estimate the median overall survival (OS). (Cohort B) VI. To evaluate safety and tolerability of MK-3475 (pembrolizumab) in this setting. (Cohort B)

OTHER OBJECTIVES:

I. To evaluate the hypothesis that higher mutational load in the patient derived baseline tumor biopsy samples is associated with higher pathologic complete response (pCR).

II. To evaluate T cell infiltration into the tumors in DM patients and correlate with response to programmed cell death protein 1 (PD-1) blockade.

III. To evaluate the clonality of tumor infiltrating T cells in DM patients and correlate with response to PD-1 blockade.

IV. To evaluate adaptive immune resistant mechanism in DM tumors.

OUTLINE: Patients are assigned to 1 of 2 cohorts.

COHORT A: Patients receive pembrolizumab intravenously (IV) over 30 minutes on day 1. Treatment repeats every 21 days for up to 3 cycles. Patients with potentially resectable disease undergo surgery. Patients with tumor progression and unresectable disease may receive one additional cycle of pembrolizumab.

COHORT B: Patients with unresectable disease receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 34 cycles in the absence of disease progression or toxicity.

After completion of study treatment, patients are followed up at 6 and 12 weeks, then every 3 months for 1 year, and every 6 months for 4 years.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 56 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II and Pilot Trial of PD-1 Blockade With MK-3475 (Pembrolizumab) in Patients With Resectable or Unresectable Desmoplastic Melanoma (DM)
Actual Study Start Date : October 20, 2016
Estimated Primary Completion Date : December 1, 2028

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Melanoma

Arm Intervention/treatment
Experimental: Cohort A (pembrolizumab, surgery)
Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 3 cycles. Patients with potentially resectable disease undergo surgery. Patients with tumor progression and unresectable disease may receive one additional cycle of pembrolizumab.
Biological: Pembrolizumab
Given IV
Other Names:
  • Keytruda
  • Lambrolizumab
  • MK-3475
  • SCH 900475

Procedure: Therapeutic Conventional Surgery
Undergo surgical resection

Active Comparator: Cohort B (pembrolizumab)
Patients with unresectable disease receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 34 cycles in the absence of disease progression or toxicity.
Biological: Pembrolizumab
Given IV
Other Names:
  • Keytruda
  • Lambrolizumab
  • MK-3475
  • SCH 900475




Primary Outcome Measures :
  1. Pathologic complete response (pCR) rate (Cohort A) [ Time Frame: Up to 5 years ]
    Pathologic complete response is defined as no evidence of viable tumor cells on complete pathological evaluation of the surgical specimen per institutional standard of care. Will assess the association between overall mutational load and pCR rate.

  2. Complete response (CR) rate (Cohort B) [ Time Frame: Up to 5 years ]
    Complete response defined as disappearance of all target and non-target lesions. Will assess the association between overall mutational load and CR rate.


Secondary Outcome Measures :
  1. Overall response rate (Cohort A) [ Time Frame: At 9 weeks ]
    Estimated with a 95% confidence interval.

  2. Overall survival rate (Cohort A and B) [ Time Frame: At 9 weeks ]
    Estimated with a 95% confidence interval.

  3. Progression free survival (Cohort A and B) [ Time Frame: At 9 weeks ]
    Estimated with a 95% confidence interval.

  4. Incidence of toxicity as measured by the National Cancer Institute Common Terminology for Adverse Events version 4.0 (Cohort A) [ Time Frame: Up to 9 weeks ]
    Toxicity will be assessed across all patients receiving pembrolizumab.


Other Outcome Measures:
  1. Change in CD8 expression (Cohort A and B) [ Time Frame: Baseline up to week 9 ]
    Will examine whether change in T-cell infiltration following treatment is higher in the DM patients who respond. The change in CD8 expression will be computed and compared to the change between responders and non-responders using a two-sample t-test.

  2. Change in T-cell receptor clonality (Cohort A and B) [ Time Frame: Baseline up to week 9 ]
    Will be compared between responders and non-responders using a two-sample t-test with significance determined at the two-sided alpha=0.05 level.

  3. Change in PD-L1 expression (Cohort A and B) [ Time Frame: Baseline up to week 9 ]
    Will examine adaptive immune resistance by first evaluating whether PD-L1 expression is increased at week 4 and week 9 as compared to baseline using paired t-tests and controlling the type I error at the two-sided alpha=0.05 level. The change in expression will be computed and then compared to the change between responders and non-responders using a two-sample t-test.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • COHORT A: Patients must have histologically or cytologically confirmed primary desmoplastic melanoma that is deemed resectable; the decision to perform surgery on patients must be based on good clinical judgment; eligible patients for surgical resection must have disease that, in the judgment of the surgeon, is deemed completely resectable resulting in free surgical margins; patients must have residual disease after initial biopsy which can be measurable or non-measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1; residual disease can either be confirmed with fine-needle aspiration (FNA) or if measurable disease is present, no FNA needs to be obtained OR
  • COHORT B: Patients must have histologically or cytologically confirmed primary desmoplastic melanoma that is unresectable; patients in Cohort B must have measurable disease per RECIST 1.1
  • Contrast-enhanced computed tomography (CT) scans of the chest, abdomen and pelvis are required; a whole body positron emission tomography (PET)/CT scan with diagnostic quality images and intravenous iodinated contrast may be used in lieu of a contrast enhanced CT of the chest, abdomen and pelvis; imaging of the head and neck is required only if the patient has a head/neck primary; contrast may be omitted if the treating investigator believes that exposure to contrast poses an excessive risk to the patient; if skin lesions are being followed as measurable disease, photograph with a ruler included and physician measurements, must be kept in the patient's chart as source documentation; all measurable lesions must be assessed within 28 days prior to registration; tests to assess non-measurable disease must be performed within 42 days prior to registration; all disease must be assessed and documented on the baseline tumor assessment form (RECIST 1.1)
  • Patients must not have known brain metastases unless brain metastases have been treated and patient is asymptomatic with no residual neurological dysfunction and has not received enzyme-reducing anti-epileptic drugs or corticosteroids for at least 14 days prior to registration
  • Patients must not have received prior systemic treatment for this melanoma
  • Patients must not be planning to receive concomitant other biologic therapy, radiation therapy, hormonal therapy, other chemotherapy, anti-cancer surgery or other anti-cancer therapy while on this protocol
  • Patients must not have received radiation therapy, non-cytotoxic agents or investigational agents or systemic corticosteroids within 14 days prior to registration
  • Patients may have received prior surgery; all adverse events associated with prior surgery must have resolved to =< grade 1 (per Common Terminology Criteria for Adverse Events [CTCAE] 4.0) prior to registration
  • Absolute neutrophil count (ANC) >= 1,500/mcl (obtained within 28 days prior to registration)
  • Platelets >= 50,000/mcl (obtained within 28 days prior to registration)
  • Hemoglobin >= 8 g/dL (obtained within 28 days prior to registration)
  • Total bilirubin =< 1.5 x institutional upper limit of normal (IULN) (or =< 3.0 x IULN with Gilbert's syndrome) (obtained within 28 days prior to registration)
  • Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x IULN (or < 5 x IULN for patients with known liver metastases) (obtained within 28 days prior to registration)
  • Patients must have lactate dehydrogenase (LDH) performed within 28 days prior to registration
  • Patients must have Zubrod performance status =< 2
  • Patients must not have history of (non-infectious) pneumonitis that required steroids or current pneumonitis
  • Patients must not have an active infection requiring systemic therapy
  • Patients must not have active autoimmune disease that has required systemic treatment in past 2 years (i.e., with use of disease modifying agents, corticosteroids or immunosuppressive drugs); replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment
  • Patients must not have received live vaccines within 42 days prior to registration; examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, chicken pox, shingles, yellow fever, rabies, Bacillus Calmette-Guerin (BCG), and typhoid (oral) vaccine; seasonal influenza vaccines for injection are allowed; however, intranasal influenza vaccines (e.g., Flu-Mist) are not allowed
  • Patients known to be human immunodeficiency virus (HIV) positive are eligible if they meet the following criteria within 30 days prior to registration: stable and adequate CD4 counts (>= 350 mm^3), and serum HIV viral load of < 25,000 IU/ml; patients must be on a stable anti-viral therapy
  • No other prior malignancy is allowed except for the following: adequately treated basal cell or squamous cell skin cancer, adequately treated in situ cancer, adequately treated stage I or II cancer (including multiple primary melanomas) from which the patient is currently in complete remission, or any other cancer from which the patient has been disease free for three years
  • Women of childbearing potential must have a negative urine or serum pregnancy test within 28 days prior to registration; women/men of reproductive potential must have agreed to use an effective contraceptive method for the course of the study through 120 days after the last dose of study medication; should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately; a woman is considered to be of "reproductive potential" if she has had menses at any time in the preceding 12 consecutive months; in addition to routine contraceptive methods, "effective contraception" also includes heterosexual celibacy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) defined as a hysterectomy, bilateral oophorectomy, or bilateral tubal ligation; however, if at any point a previously celibate patient chooses to become heterosexually active during the time period for use of contraceptive measures outlined in the protocol, he/she is responsible for beginning contraceptive measures; patients must not be pregnant or nursing
  • Patients must have specimens available and institutions must be planning to submit for centralized pathology review and for integrated translational medicine objectives
  • Patients must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines
  • As a part of the Oncology Patient Enrollment Network (OPEN) registration process, the treating institution's identity is provided in order to ensure that the current (within 365 days) date of institutional review board approval for this study has been entered in the system

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02775851


  Hide Study Locations
Locations
Layout table for location information
United States, Alaska
Fairbanks Memorial Hospital Recruiting
Fairbanks, Alaska, United States, 99701
Contact: Site Public Contact    907-458-3043    cancerresearch@foundationhealth.org   
Principal Investigator: Keren Sturtz         
United States, Arkansas
Mercy Hospital Fort Smith Recruiting
Fort Smith, Arkansas, United States, 72903
Contact: Site Public Contact    800-378-9373      
Principal Investigator: Jay W. Carlson         
United States, California
City of Hope Comprehensive Cancer Center Active, not recruiting
Duarte, California, United States, 91010
Epic Care-Dublin Recruiting
Dublin, California, United States, 94568
Contact: Site Public Contact    925-875-1677      
Principal Investigator: James H. Feusner         
Bay Area Breast Surgeons Inc Recruiting
Emeryville, California, United States, 94608
Contact: Site Public Contact    510-835-9900      
Principal Investigator: James H. Feusner         
Epic Care Partners in Cancer Care Recruiting
Emeryville, California, United States, 94608
Contact: Site Public Contact    510-629-6682      
Principal Investigator: James H. Feusner         
Los Angeles County-USC Medical Center Recruiting
Los Angeles, California, United States, 90033
Contact: Site Public Contact    323-865-0451      
Principal Investigator: Gino K. In         
USC / Norris Comprehensive Cancer Center Recruiting
Los Angeles, California, United States, 90033
Contact: Site Public Contact    323-865-0451      
Principal Investigator: Gino K. In         
UCLA / Jonsson Comprehensive Cancer Center Recruiting
Los Angeles, California, United States, 90095
Contact: Site Public Contact    888-798-0719      
Principal Investigator: Bartosz Chmielowski         
Contra Costa Regional Medical Center Recruiting
Martinez, California, United States, 94553-3156
Contact: Site Public Contact    925-957-5400      
Principal Investigator: James H. Feusner         
USC Norris Oncology/Hematology-Newport Beach Recruiting
Newport Beach, California, United States, 92663
Contact: Site Public Contact    323-865-0451      
Principal Investigator: Gino K. In         
Alta Bates Summit Medical Center - Summit Campus Recruiting
Oakland, California, United States, 94609
Contact: Site Public Contact    510-204-1414      
Principal Investigator: James H. Feusner         
Bay Area Tumor Institute Recruiting
Oakland, California, United States, 94609
Contact: Site Public Contact    510-465-2242    lradke@bati.org   
Principal Investigator: James H. Feusner         
Keck Medical Center of USC Pasadena Recruiting
Pasadena, California, United States, 91105
Contact: Site Public Contact    323-865-0451      
Principal Investigator: Gino K. In         
City of Hope South Pasadena Active, not recruiting
South Pasadena, California, United States, 91030
City of Hope Upland Active, not recruiting
Upland, California, United States, 91786
Epic Care Cyberknife Center Recruiting
Walnut Creek, California, United States, 94597
Contact: Site Public Contact    510-465-8016    somega@bati.org   
Principal Investigator: James H. Feusner         
United States, Colorado
Rocky Mountain Cancer Centers-Aurora Recruiting
Aurora, Colorado, United States, 80012
Contact: Site Public Contact    303-777-2663    ccrp@co-cancerresearch.org   
Principal Investigator: Keren Sturtz         
The Medical Center of Aurora Recruiting
Aurora, Colorado, United States, 80012
Contact: Site Public Contact    303-777-2663    ccrp@co-cancerresearch.org   
Principal Investigator: Keren Sturtz         
Boulder Community Hospital Recruiting
Boulder, Colorado, United States, 80301
Contact: Site Public Contact    303-777-2663    jbloomfield@co-cancerresearch.org   
Principal Investigator: Keren Sturtz         
Rocky Mountain Cancer Centers-Boulder Recruiting
Boulder, Colorado, United States, 80304
Contact: Site Public Contact    303-777-2663    ccrp@co-cancerresearch.org   
Principal Investigator: Keren Sturtz         
Cancer Center of Colorado at Sloan's Lake Recruiting
Denver, Colorado, United States, 80204
Contact: Site Public Contact    303-777-2663      
Principal Investigator: Keren Sturtz         
National Jewish Health-Main Campus Recruiting
Denver, Colorado, United States, 80206
Contact: Site Public Contact    877-225-5654    glicht@co-cancerresearch.org   
Principal Investigator: Keren Sturtz         
The Women's Imaging Center Recruiting
Denver, Colorado, United States, 80209
Contact: Site Public Contact    303-777-2663    ccrp@co-cancerresearch.org   
Principal Investigator: Keren Sturtz         
Colorado Blood Cancer Institute Recruiting
Denver, Colorado, United States, 80218
Contact: Site Public Contact    303-777-2663    ccrp@co-cancerresearch.org   
Principal Investigator: Keren Sturtz         
Presbyterian - Saint Lukes Medical Center - Health One Recruiting
Denver, Colorado, United States, 80218
Contact: Site Public Contact    303-777-2663    ccrp@co-cancerresearch.org   
Principal Investigator: Keren Sturtz         
Rocky Mountain Cancer Centers-Midtown Recruiting
Denver, Colorado, United States, 80218
Contact: Site Public Contact    303-777-2663    ccrp@co-cancerresearch.org   
Principal Investigator: Keren Sturtz         
SCL Health Saint Joseph Hospital Recruiting
Denver, Colorado, United States, 80218
Contact: Site Public Contact    303-777-2663    ccrp@co-cancerresearch.org   
Principal Investigator: Keren Sturtz         
Rocky Mountain Cancer Centers-Rose Recruiting
Denver, Colorado, United States, 80220
Contact: Site Public Contact    303-777-2663    ccrp@co-cancerresearch.org   
Principal Investigator: Keren Sturtz         
Rose Medical Center Recruiting
Denver, Colorado, United States, 80220
Contact: Site Public Contact    303-777-2663    ccrp@co-cancerresearch.org   
Principal Investigator: Keren Sturtz         
Western Surgical Care Recruiting
Denver, Colorado, United States, 80220
Contact: Site Public Contact    303-777-2663    ccrp@co-cancerresearch.org   
Principal Investigator: Keren Sturtz         
Mountain Blue Cancer Care Center - Swedish Recruiting
Englewood, Colorado, United States, 80113
Contact: Site Public Contact    303-777-2663    WSCR@westernstatesncorp.org   
Principal Investigator: Keren Sturtz         
Swedish Medical Center Recruiting
Englewood, Colorado, United States, 80113
Contact: Site Public Contact    303-777-2663    ccrp@co-cancerresearch.org   
Principal Investigator: Keren Sturtz         
National Jewish Health-Western Hematology Oncology Suspended
Golden, Colorado, United States, 80401
Saint Mary's Hospital and Regional Medical Center Recruiting
Grand Junction, Colorado, United States, 81501
Contact: Site Public Contact    303-777-2663    ccrp@co-cancerresearch.org   
Principal Investigator: Keren Sturtz         
Grand Valley Oncology Active, not recruiting
Grand Junction, Colorado, United States, 81505
North Colorado Medical Center Recruiting
Greeley, Colorado, United States, 80631
Contact: Site Public Contact    303-777-2663    ccrp@co-cancerresearch.org   
Principal Investigator: Keren Sturtz         
Good Samaritan Medical Center Recruiting
Lafayette, Colorado, United States, 80026
Contact: Site Public Contact    303-673-1622      
Principal Investigator: Keren Sturtz         
Rocky Mountain Cancer Centers-Littleton Recruiting
Littleton, Colorado, United States, 80120
Contact: Site Public Contact    303-777-2663    ccrp@co-cancerresearch.org   
Principal Investigator: Keren Sturtz         
Rocky Mountain Cancer Centers-Sky Ridge Recruiting
Lone Tree, Colorado, United States, 80124
Contact: Site Public Contact    303-777-2663    ccrp@co-cancerresearch.org   
Principal Investigator: Keren Sturtz         
Sky Ridge Medical Center Recruiting
Lone Tree, Colorado, United States, 80124
Contact: Site Public Contact    303-777-2663    ccrp@co-cancerresearch.org   
Principal Investigator: Keren Sturtz         
McKee Medical Center Recruiting
Loveland, Colorado, United States, 80539
Contact: Site Public Contact    303-777-2663    ccrp@co-cancerresearch.org   
Principal Investigator: Keren Sturtz         
National Jewish Health-Northern Hematology Oncology Recruiting
Thornton, Colorado, United States, 80260
Contact: Site Public Contact    303-777-2663    glicht@co-cancerresearch.org   
Principal Investigator: Keren Sturtz         
SCL Health Lutheran Medical Center Recruiting
Wheat Ridge, Colorado, United States, 80033
Contact: Site Public Contact    303-777-2663    ccrp@co-cancerresearch.org   
Principal Investigator: Keren Sturtz         
United States, Connecticut
Hartford Hospital Recruiting
Hartford, Connecticut, United States, 06102
Contact: Site Public Contact    860-545-5363      
Principal Investigator: Omar Eton         
United States, Florida
Mount Sinai Comprehensive Cancer Center at Aventura Recruiting
Aventura, Florida, United States, 33180
Contact: Site Public Contact    305-674-2625    yenrique@msmc.com   
Principal Investigator: Jose Lutzky         
Holy Cross Hospital Suspended
Fort Lauderdale, Florida, United States, 33308
Mount Sinai Medical Center Recruiting
Miami Beach, Florida, United States, 33140
Contact: Site Public Contact    305-674-2625    yenrique@msmc.com   
Principal Investigator: Jose Lutzky         
Moffitt Cancer Center-International Plaza Recruiting
Tampa, Florida, United States, 33607
Contact: Site Public Contact    800-679-0775    canceranswers@moffitt.org   
Principal Investigator: Zeynep Eroglu         
Moffitt Cancer Center - McKinley Campus Recruiting
Tampa, Florida, United States, 33612
Contact: Site Public Contact    800-679-0775    canceranswers@moffitt.org   
Principal Investigator: Zeynep Eroglu         
Moffitt Cancer Center Recruiting
Tampa, Florida, United States, 33612
Contact: Site Public Contact    800-679-0775    canceranswers@moffitt.org   
Principal Investigator: Zeynep Eroglu         
United States, Georgia
Lewis Cancer and Research Pavilion at Saint Joseph's/Candler Recruiting
Savannah, Georgia, United States, 31405
Contact: Site Public Contact    912-819-5704    underberga@sjchs.org   
Principal Investigator: Howard A. Zaren         
Low Country Cancer Care Associates PC Suspended
Savannah, Georgia, United States, 31405
Summit Cancer Care-Candler Recruiting
Savannah, Georgia, United States, 31405
Contact: Site Public Contact       protocols@swog.org   
Principal Investigator: Howard A. Zaren         
United States, Idaho
Saint Alphonsus Cancer Care Center-Boise Recruiting
Boise, Idaho, United States, 83706
Contact: Site Public Contact    734-712-3671    stephanie.couch@stjoeshealth.org   
Principal Investigator: John M. Schallenkamp         
Saint Alphonsus Cancer Care Center-Caldwell Recruiting
Caldwell, Idaho, United States, 83605
Contact: Site Public Contact    734-712-3671    stephanie.couch@stjoeshealth.org   
Principal Investigator: John M. Schallenkamp         
Kootenai Medical Center Recruiting
Coeur d'Alene, Idaho, United States, 83814
Contact: Site Public Contact    406-969-6060    mccinfo@mtcancer.org   
Principal Investigator: John M. Schallenkamp         
Walter Knox Memorial Hospital Recruiting
Emmett, Idaho, United States, 83617
Contact: Site Public Contact    734-712-3671    stephanie.couch@stjoeshealth.org   
Principal Investigator: John M. Schallenkamp         
Idaho Urologic Institute-Meridian Recruiting
Meridian, Idaho, United States, 83642
Contact: Site Public Contact    734-712-3671    stephanie.couch@stjoeshealth.org   
Principal Investigator: John M. Schallenkamp         
Saint Alphonsus Medical Center-Nampa Recruiting
Nampa, Idaho, United States, 83686
Contact: Site Public Contact    734-712-3671    stephanie.couch@stjoeshealth.org   
Principal Investigator: John M. Schallenkamp         
Kootenai Cancer Center Recruiting
Post Falls, Idaho, United States, 83854
Contact: Site Public Contact    406-969-6060    mccinfo@mtcancer.org   
Principal Investigator: John M. Schallenkamp         
Kootenai Cancer Clinic Recruiting
Sandpoint, Idaho, United States, 83864
Contact: Site Public Contact    406-969-6060    mccinfo@mtcancer.org   
Principal Investigator: John M. Schallenkamp         
United States, Illinois
Rush - Copley Medical Center Recruiting
Aurora, Illinois, United States, 60504
Contact: Site Public Contact    630-978-6212    Cancer.Research@rushcopley.com   
Principal Investigator: James R. Egner         
Northwestern University Recruiting
Chicago, Illinois, United States, 60611
Contact: Site Public Contact    312-695-1301    cancer@northwestern.edu   
Principal Investigator: Sunandana Chandra         
Carle on Vermilion Recruiting
Danville, Illinois, United States, 61832
Contact: Site Public Contact    800-446-5532    Research@carle.com   
Principal Investigator: James R. Egner         
Carle Physician Group-Effingham Recruiting
Effingham, Illinois, United States, 62401
Contact: Site Public Contact    800-446-5532    Research@carle.com   
Principal Investigator: James R. Egner         
Northwestern Medicine Cancer Center Delnor Recruiting
Geneva, Illinois, United States, 60134
Contact: Site Public Contact    630-315-1918    Claudine.Gamster@CadenceHealth.org   
Principal Investigator: Arlene D'Souza         
Northwestern Medicine Lake Forest Hospital Recruiting
Lake Forest, Illinois, United States, 60045
Contact: Site Public Contact       cancertrials@northwestern.edu   
Principal Investigator: Sunandana Chandra         
Carle Physician Group-Mattoon/Charleston Recruiting
Mattoon, Illinois, United States, 61938
Contact: Site Public Contact    800-446-5532    Research@carle.com   
Principal Investigator: James R. Egner         
Good Samaritan Regional Health Center Recruiting
Mount Vernon, Illinois, United States, 62864
Contact: Site Public Contact    618-242-4600      
Principal Investigator: Jay W. Carlson         
Carle Cancer Center Recruiting
Urbana, Illinois, United States, 61801
Contact: Site Public Contact    800-446-5532    Research@carle.com   
Principal Investigator: James R. Egner         
The Carle Foundation Hospital Recruiting
Urbana, Illinois, United States, 61801
Contact: Site Public Contact    800-446-5532    Research@carle.com   
Principal Investigator: James R. Egner         
Northwestern Medicine Cancer Center Warrenville Recruiting
Warrenville, Illinois, United States, 60555
Contact: Site Public Contact    630-315-1918    Claudine.Gamster@CadenceHealth.org   
Principal Investigator: Arlene D'Souza         
Rush-Copley Healthcare Center Recruiting
Yorkville, Illinois, United States, 60560
Contact: Site Public Contact    630-978-6212    Cancer.Research@rushcopley.com   
Principal Investigator: James R. Egner         
United States, Indiana
Deaconess Clinic Downtown Recruiting
Evansville, Indiana, United States, 47713
Contact: Site Public Contact    877-654-0311    Research@Deaconess.com   
Principal Investigator: James R. Egner         
Chancellor Center for Oncology Recruiting
Newburgh, Indiana, United States, 47630
Contact: Site Public Contact    877-654-0311    Research@Deaconess.com   
Principal Investigator: James R. Egner         
United States, Kansas
Coffeyville Regional Medical Center Recruiting
Coffeyville, Kansas, United States, 67337
Contact: Site Public Contact    620-252-1606      
Principal Investigator: Gary C. Doolittle         
University of Kansas Clinical Research Center Active, not recruiting
Fairway, Kansas, United States, 66205
Central Care Cancer Center - Garden City Active, not recruiting
Garden City, Kansas, United States, 67846
Central Care Cancer Center - Great Bend Active, not recruiting
Great Bend, Kansas, United States, 67530
Hays Medical Center Recruiting
Hays, Kansas, United States, 67601
Contact: Site Public Contact    785-623-5774      
Principal Investigator: Gary C. Doolittle         
University of Kansas Cancer Center-West Recruiting
Kansas City, Kansas, United States, 66112
Contact: Site Public Contact    913-945-7552    ctnursenav@kumc.edu   
Principal Investigator: Gary C. Doolittle         
University of Kansas Cancer Center Active, not recruiting
Kansas City, Kansas, United States, 66160
Kansas Institute of Medicine Cancer and Blood Center Active, not recruiting
Lenexa, Kansas, United States, 66219
Minimally Invasive Surgery Hospital Active, not recruiting
Lenexa, Kansas, United States, 66219
Olathe Medical Center Recruiting
Olathe, Kansas, United States, 66061
Contact: Site Public Contact    913-791-3500    Jeni.wakefield@olathehealth.org   
Principal Investigator: Gary C. Doolittle         
Menorah Medical Center Active, not recruiting
Overland Park, Kansas, United States, 66209
University of Kansas Cancer Center-Overland Park Recruiting
Overland Park, Kansas, United States, 66210
Contact: Site Public Contact    913-945-7552    ctnursenav@kumc.edu   
Principal Investigator: Gary C. Doolittle         
Via Christi Hospital-Pittsburg Recruiting
Pittsburg, Kansas, United States, 66762
Contact: Site Public Contact    620-235-7900      
Principal Investigator: Gary C. Doolittle         
Salina Regional Health Center Recruiting
Salina, Kansas, United States, 67401
Contact: Site Public Contact    785-452-7038    kkavoura@srhc.com   
Principal Investigator: Gary C. Doolittle         
Saint Francis Hospital and Medical Center - Topeka Recruiting
Topeka, Kansas, United States, 66606
Contact: Site Public Contact    785-295-8000      
Principal Investigator: Gary C. Doolittle         
University of Kansas Hospital-Westwood Cancer Center Recruiting
Westwood, Kansas, United States, 66205
Contact: Site Public Contact    913-945-7552    ctnursenav@kumc.edu   
Principal Investigator: Gary C. Doolittle         
United States, Michigan
Henry Ford Cancer Institute-Downriver Recruiting
Brownstown, Michigan, United States, 48183
Contact: Site Public Contact    313-916-3721    CTOResearch@hfhs.org   
Principal Investigator: Ding Wang         
Henry Ford Macomb Hospital-Clinton Township Recruiting
Clinton Township, Michigan, United States, 48038
Contact: Site Public Contact    313-916-3721    CTOResearch@hfhs.org   
Principal Investigator: Ding Wang         
Henry Ford Medical Center-Fairlane Recruiting
Dearborn, Michigan, United States, 48126
Contact: Site Public Contact    313-916-3721    CTOResearch@hfhs.org   
Principal Investigator: Ding Wang         
Henry Ford Hospital Recruiting
Detroit, Michigan, United States, 48202
Contact: Site Public Contact    313-916-3721    CTOResearch@hfhs.org   
Principal Investigator: Ding Wang         
Allegiance Health Recruiting
Jackson, Michigan, United States, 49201
Contact: Site Public Contact    313-916-3721    CTOResearch@hfhs.org   
Principal Investigator: Ding Wang         
Monroe Cancer Center Recruiting
Monroe, Michigan, United States, 48162
Contact: Site Public Contact    888-823-5923    ctsucontact@westat.com   
Principal Investigator: Abhijit B. Saste         
Henry Ford Medical Center-Columbus Recruiting
Novi, Michigan, United States, 48377
Contact: Site Public Contact    313-916-3721    CTOResearch@hfhs.org   
Principal Investigator: Ding Wang         
Henry Ford West Bloomfield Hospital Recruiting
West Bloomfield, Michigan, United States, 48322
Contact: Site Public Contact    313-916-3721    CTOResearch@hfhs.org   
Principal Investigator: Ding Wang         
United States, Minnesota
Fairview Ridges Hospital Recruiting
Burnsville, Minnesota, United States, 55337
Contact: Site Public Contact    952-993-1517    mmcorc@healthpartners.com   
Principal Investigator: David M. King         
Cambridge Medical Center Recruiting
Cambridge, Minnesota, United States, 55008
Contact: Site Public Contact    952-993-1517    mmcorc@healthpartners.com   
Principal Investigator: David M. King         
Mercy Hospital Recruiting
Coon Rapids, Minnesota, United States, 55433
Contact: Site Public Contact    952-993-1517    mmcorc@healthpartners.com   
Principal Investigator: David M. King         
Fairview-Southdale Hospital Recruiting
Edina, Minnesota, United States, 55435
Contact: Site Public Contact    952-993-1517    mmcorc@healthpartners.com   
Principal Investigator: David M. King         
Unity Hospital Recruiting
Fridley, Minnesota, United States, 55432
Contact: Site Public Contact    952-993-1517    mmcorc@healthpartners.com   
Principal Investigator: David M. King         
Fairview Maple Grove Medical Center Recruiting
Maple Grove, Minnesota, United States, 55369
Contact: Site Public Contact    952-993-1517    mmcorc@healthpartners.com   
Principal Investigator: David M. King         
Minnesota Oncology Hematology PA-Maplewood Recruiting
Maplewood, Minnesota, United States, 55109
Contact: Site Public Contact    952-993-1517    mmcorc@healthpartners.com   
Principal Investigator: David M. King         
Saint John's Hospital - Healtheast Recruiting
Maplewood, Minnesota, United States, 55109
Contact: Site Public Contact    952-993-1517    mmcorc@healthpartners.com   
Principal Investigator: David M. King         
Abbott-Northwestern Hospital Recruiting
Minneapolis, Minnesota, United States, 55407
Contact: Site Public Contact    952-993-1517    mmcorc@healthpartners.com   
Principal Investigator: David M. King         
Hennepin County Medical Center Recruiting
Minneapolis, Minnesota, United States, 55415
Contact: Site Public Contact    952-993-1517    mmcorc@healthpartners.com   
Principal Investigator: David M. King         
Health Partners Inc Recruiting
Minneapolis, Minnesota, United States, 55454
Contact: Site Public Contact    952-993-1517    mmcorc@healthpartners.com   
Principal Investigator: David M. King         
Monticello Cancer Center Recruiting
Monticello, Minnesota, United States, 55362
Contact: Site Public Contact    952-993-1517    mmcorc@healthpartners.com   
Principal Investigator: David M. King         
New Ulm Medical Center Recruiting
New Ulm, Minnesota, United States, 56073
Contact: Site Public Contact    952-993-1517    mmcorc@healthpartners.com   
Principal Investigator: David M. King         
Fairview Northland Medical Center Recruiting
Princeton, Minnesota, United States, 55371
Contact: Site Public Contact    952-993-1517    mmcorc@healthpartners.com   
Principal Investigator: David M. King         
North Memorial Medical Health Center Recruiting
Robbinsdale, Minnesota, United States, 55422
Contact: Site Public Contact    952-993-1517    mmcorc@healthpartners.com   
Principal Investigator: David M. King         
Park Nicollet Clinic - Saint Louis Park Recruiting
Saint Louis Park, Minnesota, United States, 55416
Contact: Site Public Contact    952-993-1517    mmcorc@healthpartners.com   
Principal Investigator: David M. King         
Regions Hospital Recruiting
Saint Paul, Minnesota, United States, 55101
Contact: Site Public Contact    952-993-1517    mmcorc@healthpartners.com   
Principal Investigator: David M. King         
United Hospital Recruiting
Saint Paul, Minnesota, United States, 55102
Contact: Site Public Contact    952-993-1517    mmcorc@healthpartners.com   
Principal Investigator: David M. King         
Saint Francis Regional Medical Center Recruiting
Shakopee, Minnesota, United States, 55379
Contact: Site Public Contact    952-993-1517    mmcorc@healthpartners.com   
Principal Investigator: David M. King         
Lakeview Hospital Recruiting
Stillwater, Minnesota, United States, 55082
Contact: Site Public Contact    952-993-1517    mmcorc@healthpartners.com   
Principal Investigator: David M. King         
Ridgeview Medical Center Recruiting
Waconia, Minnesota, United States, 55387
Contact: Site Public Contact    952-993-1517    mmcorc@healthpartners.com   
Principal Investigator: David M. King         
Rice Memorial Hospital Recruiting
Willmar, Minnesota, United States, 56201
Contact: Site Public Contact    952-993-1517    mmcorc@healthpartners.com   
Principal Investigator: David M. King         
Minnesota Oncology Hematology PA-Woodbury Recruiting
Woodbury, Minnesota, United States, 55125
Contact: Site Public Contact    952-993-1517    mmcorc@healthpartners.com   
Principal Investigator: David M. King         
Fairview Lakes Medical Center Recruiting
Wyoming, Minnesota, United States, 55092
Contact: Site Public Contact    952-993-1517    mmcorc@healthpartners.com   
Principal Investigator: David M. King         
United States, Mississippi
Singing River Hospital Recruiting
Pascagoula, Mississippi, United States, 39581
Contact: Site Public Contact    228-809-5292      
Principal Investigator: James E. Clarkson         
United States, Missouri
Saint Louis Cancer and Breast Institute-Ballwin Recruiting
Ballwin, Missouri, United States, 63011
Contact: Site Public Contact    314-251-7058      
Principal Investigator: Jay W. Carlson         
Central Care Cancer Center - Bolivar Active, not recruiting
Bolivar, Missouri, United States, 65613
Cox Cancer Center Branson Recruiting
Branson, Missouri, United States, 65616
Contact: Site Public Contact    417-269-4520      
Principal Investigator: Jay W. Carlson         
Centerpoint Medical Center LLC Active, not recruiting
Independence, Missouri, United States, 64057
Freeman Health System Recruiting
Joplin, Missouri, United States, 64804
Contact: Site Public Contact    417-347-4030    LJCrockett@freemanhealth.com   
Principal Investigator: Jay W. Carlson         
Mercy Hospital Joplin Recruiting
Joplin, Missouri, United States, 64804
Contact: Site Public Contact    417-556-3074    esmeralda.carrillo@mercy.net   
Principal Investigator: Jay W. Carlson         
Truman Medical Center Recruiting
Kansas City, Missouri, United States, 64108
Contact: Site Public Contact    816-404-4375      
Principal Investigator: Gary C. Doolittle         
The University of Kansas Cancer Center-South Suspended
Kansas City, Missouri, United States, 64131
Research Medical Center Active, not recruiting
Kansas City, Missouri, United States, 64132
The University of Kansas Cancer Center-North Recruiting
Kansas City, Missouri, United States, 64154
Contact: Site Public Contact    913-945-7552    ctnursenav@kumc.edu   
Principal Investigator: Gary C. Doolittle         
The University of Kansas Cancer Center-Lee's Summit Recruiting
Lee's Summit, Missouri, United States, 64064
Contact: Site Public Contact    913-945-7552    ctnursenav@kumc.edu   
Principal Investigator: Gary C. Doolittle         
Delbert Day Cancer Institute at PCRMC Recruiting
Rolla, Missouri, United States, 65401
Contact: Site Public Contact    573-458-7504    jrichards@research.pcrmc.com   
Principal Investigator: Jay W. Carlson         
Mercy Clinic-Rolla-Cancer and Hematology Recruiting
Rolla, Missouri, United States, 65401
Contact: Site Public Contact    573-458-7504    jrichards@research.pcrmc.com   
Principal Investigator: Jay W. Carlson         
Heartland Regional Medical Center Recruiting
Saint Joseph, Missouri, United States, 64507
Contact: Site Public Contact    816-271-7937    linda.schumacher@mymlc.com   
Principal Investigator: Jay W. Carlson         
Saint Louis Cancer and Breast Institute-South City Recruiting
Saint Louis, Missouri, United States, 63109
Contact: Site Public Contact    314-353-1870      
Principal Investigator: Jay W. Carlson         
Mercy Hospital South Recruiting
Saint Louis, Missouri, United States, 63128
Contact: Site Public Contact       janet.lesko@mercy.net   
Principal Investigator: Jay W. Carlson         
Mercy Hospital Saint Louis Recruiting
Saint Louis, Missouri, United States, 63141
Contact: Site Public Contact    314-251-7066      
Principal Investigator: Jay W. Carlson         
Mercy Hospital Springfield Recruiting
Springfield, Missouri, United States, 65804
Contact: Site Public Contact    417-269-4520      
Principal Investigator: Jay W. Carlson         
CoxHealth South Hospital Recruiting
Springfield, Missouri, United States, 65807
Contact: Site Public Contact    417-269-4520      
Principal Investigator: Jay W. Carlson         
Mercy Hospital Washington Recruiting
Washington, Missouri, United States, 63090
Contact: Site Public Contact    636-390-1600      
Principal Investigator: Jay W. Carlson         
United States, Montana
Community Hospital of Anaconda Recruiting
Anaconda, Montana, United States, 59711
Contact: Site Public Contact    406-969-6060    mccinfo@mtcancer.org   
Principal Investigator: John M. Schallenkamp         
Billings Clinic Cancer Center Recruiting
Billings, Montana, United States, 59101
Contact: Site Public Contact    800-996-2663    research@billingsclinic.org   
Principal Investigator: John M. Schallenkamp         
Saint Vincent Healthcare Suspended
Billings, Montana, United States, 59101
Saint Vincent Frontier Cancer Center Suspended
Billings, Montana, United States, 59102
Bozeman Deaconess Hospital Recruiting
Bozeman, Montana, United States, 59715
Contact: Site Public Contact    406-969-6060    mccinfo@mtcancer.org   
Principal Investigator: John M. Schallenkamp         
Saint James Community Hospital and Cancer Treatment Center Recruiting
Butte, Montana, United States, 59701
Contact: Site Public Contact    406-723-2621      
Principal Investigator: Keren Sturtz         
Benefis Healthcare- Sletten Cancer Institute Recruiting
Great Falls, Montana, United States, 59405
Contact: Site Public Contact    406-969-6060    mccinfo@mtcancer.org   
Principal Investigator: John M. Schallenkamp         
Great Falls Clinic Recruiting
Great Falls, Montana, United States, 59405
Contact: Site Public Contact    406-969-6060    mccinfo@mtcancer.org   
Principal Investigator: John M. Schallenkamp         
Saint Peter's Community Hospital Suspended
Helena, Montana, United States, 59601
Kalispell Regional Medical Center Recruiting
Kalispell, Montana, United States, 59901
Contact: Site Public Contact    406-969-6060    mccinfo@mtcancer.org   
Principal Investigator: John M. Schallenkamp         
Community Medical Hospital Recruiting
Missoula, Montana, United States, 59804
Contact: Site Public Contact    406-969-6060    mccinfo@mtcancer.org   
Principal Investigator: John M. Schallenkamp         
United States, New York
Roswell Park Cancer Institute Recruiting
Buffalo, New York, United States, 14263
Contact: Site Public Contact    800-767-9355    askroswell@roswellpark.org   
Principal Investigator: Marc S. Ernstoff         
United States, North Carolina
Southeastern Medical Oncology Center-Clinton Recruiting
Clinton, North Carolina, United States, 28328
Contact: Site Public Contact    919-587-9077    ecooke@cancersmoc.com   
Principal Investigator: Nagesh H. Jayaram         
Southeastern Medical Oncology Center-Goldsboro Recruiting
Goldsboro, North Carolina, United States, 27534
Contact: Site Public Contact    919-587-9077    ecooke@cancersmoc.com   
Principal Investigator: Nagesh H. Jayaram         
Wayne Memorial Hospital Active, not recruiting
Goldsboro, North Carolina, United States, 27534
Onslow Memorial Hospital Active, not recruiting
Jacksonville, North Carolina, United States, 28546
Southeastern Medical Oncology Center-Jacksonville Recruiting
Jacksonville, North Carolina, United States, 28546
Contact: Site Public Contact    910-353-0824    ecooke@cancersmoc.com   
Principal Investigator: Nagesh H. Jayaram         
United States, Ohio
Strecker Cancer Center-Belpre Recruiting
Belpre, Ohio, United States, 45714
Contact: Site Public Contact    800-523-3977    sheree@columbusccop.org   
Principal Investigator: Timothy D. Moore         
Adena Regional Medical Center Recruiting
Chillicothe, Ohio, United States, 45601
Contact: Site Public Contact    877-779-7585    sheree@columbusccop.org   
Principal Investigator: Timothy D. Moore         
Ohio State University Comprehensive Cancer Center Recruiting
Columbus, Ohio, United States, 43210
Contact: Site Public Contact    800-293-5066    Jamesline@osumc.edu   
Principal Investigator: Kari L. Kendra         
Mount Carmel East Hospital Recruiting
Columbus, Ohio, United States, 43213
Contact: Site Public Contact    614-488-2118    sheree@columbusccop.org   
Principal Investigator: Timothy D. Moore         
Columbus Oncology and Hematology Associates Inc Recruiting
Columbus, Ohio, United States, 43214
Contact: Site Public Contact    614-488-2118    sheree@columbusccop.org   
Principal Investigator: Timothy D. Moore         
Riverside Methodist Hospital Recruiting
Columbus, Ohio, United States, 43214
Contact: Site Public Contact    614-566-4475    sheree@columbusccop.org   
Principal Investigator: Timothy D. Moore         
Grant Medical Center Recruiting
Columbus, Ohio, United States, 43215
Contact: Site Public Contact    614-566-4475    sheree@columbusccop.org   
Principal Investigator: Timothy D. Moore         
The Mark H Zangmeister Center Recruiting
Columbus, Ohio, United States, 43219
Contact: Site Public Contact    614-488-2118    sheree@columbusccop.org   
Principal Investigator: Timothy D. Moore         
Mount Carmel Health Center West Recruiting
Columbus, Ohio, United States, 43222
Contact: Site Public Contact    614-234-5433    sheree@columbusccop.org   
Principal Investigator: Timothy D. Moore         
Doctors Hospital Recruiting
Columbus, Ohio, United States, 43228
Contact: Site Public Contact    614-566-3275    sheree@columbusccop.org   
Principal Investigator: Timothy D. Moore         
Delaware Health Center-Grady Cancer Center Recruiting
Delaware, Ohio, United States, 43015
Contact: Site Public Contact    740-615-0227    sheree@columbusccop.org   
Principal Investigator: Timothy D. Moore         
Delaware Radiation Oncology Suspended
Delaware, Ohio, United States, 43015
Grady Memorial Hospital Recruiting
Delaware, Ohio, United States, 43015
Contact: Site Public Contact    740-615-2403    sheree@columbusccop.org   
Principal Investigator: Timothy D. Moore         
Dublin Methodist Hospital Recruiting
Dublin, Ohio, United States, 43016
Contact: Site Public Contact    800-752-9119    sheree@columbusccop.org   
Principal Investigator: Timothy D. Moore         
Fairfield Medical Center Recruiting
Lancaster, Ohio, United States, 43130
Contact: Site Public Contact    740-687-8863    sheree@columbusccop.org   
Principal Investigator: Timothy D. Moore         
OhioHealth Mansfield Hospital Recruiting
Mansfield, Ohio, United States, 44903
Contact: Site Public Contact    419-526-8018    sheree@columbusccop.org   
Principal Investigator: Timothy D. Moore         
Marietta Memorial Hospital Recruiting
Marietta, Ohio, United States, 45750
Contact: Site Public Contact    800-523-3977    sheree@columbusccop.org   
Principal Investigator: Timothy D. Moore         
OhioHealth Marion General Hospital Recruiting
Marion, Ohio, United States, 43302
Contact: Site Public Contact    614-488-2118    sheree@columbusccop.org   
Principal Investigator: Timothy D. Moore         
Knox Community Hospital Recruiting
Mount Vernon, Ohio, United States, 43050
Contact: Site Public Contact    740-393-9000    sheree@columbusccop.org   
Principal Investigator: Timothy D. Moore         
Licking Memorial Hospital Recruiting
Newark, Ohio, United States, 43055
Contact: Site Public Contact    740-348-4000    sheree@columbusccop.org   
Principal Investigator: Timothy D. Moore         
Newark Radiation Oncology Recruiting
Newark, Ohio, United States, 43055
Contact: Site Public Contact    614-488-2118    sheree@columbusccop.org   
Principal Investigator: Timothy D. Moore         
Southern Ohio Medical Center Recruiting
Portsmouth, Ohio, United States, 45662
Contact: Site Public Contact    614-488-2118    sheree@columbusccop.org   
Principal Investigator: Timothy D. Moore         
ProMedica Flower Hospital Recruiting
Sylvania, Ohio, United States, 43560
Contact: Site Public Contact    419-824-1842      
Principal Investigator: Abhijit B. Saste         
The Toledo Hospital/Toledo Children's Hospital Recruiting
Toledo, Ohio, United States, 43606
Contact: Site Public Contact    419-824-1842      
Principal Investigator: Abhijit B. Saste         
Saint Ann's Hospital Recruiting
Westerville, Ohio, United States, 43081
Contact: Site Public Contact    614-234-5433    sheree@columbusccop.org   
Principal Investigator: Timothy D. Moore         
Genesis Healthcare System Cancer Care Center Recruiting
Zanesville, Ohio, United States, 43701
Contact: Site Public Contact    740-454-5232    sheree@columbusccop.org   
Principal Investigator: Timothy D. Moore         
United States, Oklahoma
University of Oklahoma Health Sciences Center Recruiting
Oklahoma City, Oklahoma, United States, 73104
Contact: Site Public Contact    405-271-8777    ou-clinical-trials@ouhsc.edu   
Principal Investigator: Alexandra P. Ikeguchi         
Mercy Hospital Oklahoma City Recruiting
Oklahoma City, Oklahoma, United States, 73120
Contact: Site Public Contact    405-752-3402      
Principal Investigator: Jay W. Carlson         
United States, Oregon
Saint Alphonsus Medical Center-Baker City Recruiting
Baker City, Oregon, United States, 97814
Contact: Site Public Contact    734-712-3671    stephanie.couch@stjoeshealth.org   
Principal Investigator: John M. Schallenkamp         
Saint Alphonsus Medical Center-Ontario Recruiting
Ontario, Oregon, United States, 97914
Contact: Site Public Contact    734-712-3671    stephanie.couch@stjoeshealth.org   
Principal Investigator: John M. Schallenkamp         
United States, Utah
American Fork Hospital / Huntsman Intermountain Cancer Center Recruiting
American Fork, Utah, United States, 84003
Contact: Site Public Contact    801-855-4100    officeofresearch@imail.org   
Principal Investigator: Tawnya L. Bowles         
Sandra L Maxwell Cancer Center Recruiting
Cedar City, Utah, United States, 84720
Contact: Site Public Contact    435-868-5680    officeofresearch@imail.org   
Principal Investigator: Tawnya L. Bowles         
Farmington Health Center Suspended
Farmington, Utah, United States, 84025
Logan Regional Hospital Recruiting
Logan, Utah, United States, 84321
Contact: Site Public Contact    435-716-6400    officeofresearch@imail.org   
Principal Investigator: Keren Sturtz         
Intermountain Medical Center Recruiting
Murray, Utah, United States, 84107
Contact: Site Public Contact    801-507-3950    officeofresearch@imail.org   
Principal Investigator: Keren Sturtz         
McKay-Dee Hospital Center Recruiting
Ogden, Utah, United States, 84403
Contact: Site Public Contact    801-387-7426    officeofresearch@imail.org   
Principal Investigator: Keren Sturtz         
Utah Valley Regional Medical Center Recruiting
Provo, Utah, United States, 84604
Contact: Site Public Contact    801-357-7965    officeofresearch@imail.org   
Principal Investigator: Keren Sturtz         
Riverton Hospital Recruiting
Riverton, Utah, United States, 84065
Contact: Site Public Contact    801-507-3950    officeofresearch@imail.org   
Principal Investigator: Tawnya L. Bowles         
Dixie Medical Center Regional Cancer Center Recruiting
Saint George, Utah, United States, 84770
Contact: Site Public Contact    435-688-4167    officeofresearch@imail.org   
Principal Investigator: Tawnya L. Bowles         
Utah Cancer Specialists-Salt Lake City Recruiting
Salt Lake City, Utah, United States, 84106
Contact: Site Public Contact    801-933-6070    officeofresearch@imail.org   
Principal Investigator: Tawnya L. Bowles         
Huntsman Cancer Institute/University of Utah Recruiting
Salt Lake City, Utah, United States, 84112
Contact: Site Public Contact    888-424-2100    cancerinfo@hci.utah.edu   
Principal Investigator: Siwen Hu-Lieskovan         
LDS Hospital Recruiting
Salt Lake City, Utah, United States, 84143
Contact: Site Public Contact    801-408-1347    officeofresearch@imail.org   
Principal Investigator: Keren Sturtz         
South Jordan Health Center Suspended
South Jordan, Utah, United States, 84009
United States, Washington
MultiCare Auburn Medical Center Recruiting
Auburn, Washington, United States, 98001
Contact: Site Public Contact    253-887-9333    research@multicare.org   
Principal Investigator: Keren Sturtz         
MultiCare Gig Harbor Medical Park Recruiting
Gig Harbor, Washington, United States, 98335
Contact: Site Public Contact    253-403-2394    research@multicare.org   
Principal Investigator: Keren Sturtz         
Jefferson Healthcare Recruiting
Port Townsend, Washington, United States, 98368
Contact: Site Public Contact    360-344-3091      
Principal Investigator: Keren Sturtz         
MultiCare Good Samaritan Hospital Recruiting
Puyallup, Washington, United States, 98372
Contact: Site Public Contact    800-351-7955    research@multicare.org   
Principal Investigator: Keren Sturtz         
Rockwood Clinic Cancer Treatment Center-Valley Recruiting
Spokane Valley, Washington, United States, 99216
Contact: Site Public Contact    509-724-4454    apope@rockwoodclinic.com   
Principal Investigator: Keren Sturtz         
Rockwood Cancer Treatment Center-DHEC-Downtown Recruiting
Spokane, Washington, United States, 99204
Contact: Site Public Contact    509-724-4454    apope@rockwoodclinic.com   
Principal Investigator: Keren Sturtz         
Rockwood North Cancer Treatment Center Recruiting
Spokane, Washington, United States, 99218
Contact: Site Public Contact    509-724-4454    apope@rockwoodclinic.com   
Principal Investigator: Keren Sturtz         
Mary Bridge Children's Hospital and Health Center Recruiting
Tacoma, Washington, United States, 98405
Contact: Site Public Contact    253-403-1461    research@multicare.org   
Principal Investigator: Keren Sturtz         
MultiCare Tacoma General Hospital Recruiting
Tacoma, Washington, United States, 98405
Contact: Site Public Contact    253-403-3229    research@multicare.org   
Principal Investigator: Keren Sturtz         
United States, Wisconsin
Cancer Center of Western Wisconsin Recruiting
New Richmond, Wisconsin, United States, 54017
Contact: Site Public Contact    952-993-1517    mmcorc@healthpartners.com   
Principal Investigator: David M. King         
United States, Wyoming
Cheyenne Regional Medical Center-West Recruiting
Cheyenne, Wyoming, United States, 82001
Contact: Site Public Contact    303-777-2663    ccrp@co-cancerresearch.org   
Principal Investigator: Keren Sturtz         
Billings Clinic-Cody Recruiting
Cody, Wyoming, United States, 82414
Contact: Site Public Contact    800-996-2663    research@billingsclinic.org   
Principal Investigator: John M. Schallenkamp         
Welch Cancer Center Recruiting
Sheridan, Wyoming, United States, 82801
Contact: Site Public Contact    406-969-6060    mccinfo@mtcancer.org   
Principal Investigator: John M. Schallenkamp         
Sponsors and Collaborators
National Cancer Institute (NCI)
Investigators
Layout table for investigator information
Principal Investigator: Kari L Kendra Southwest Oncology Group

Layout table for additonal information
Responsible Party: National Cancer Institute (NCI)
ClinicalTrials.gov Identifier: NCT02775851     History of Changes
Other Study ID Numbers: NCI-2016-00666
NCI-2016-00666 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) )
S1512
S1512 ( Other Identifier: SWOG )
S1512 ( Other Identifier: CTEP )
U10CA180888 ( U.S. NIH Grant/Contract )
First Posted: May 18, 2016    Key Record Dates
Last Update Posted: October 4, 2019
Last Verified: July 2019
Additional relevant MeSH terms:
Layout table for MeSH terms
Melanoma
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Nerve Tissue
Nevi and Melanomas
Pembrolizumab
Antineoplastic Agents, Immunological
Antineoplastic Agents